1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
78.35 USD   -0.14%
06/30DEXCOM SCHEDULES SECOND QUARTER 2022 EARNINGS RELEASE AND CONFERENCE CALL FOR JULY 28, 2022 AT 4 : 30 p.m. Eastern Time.
BU
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness Week, Celebrating You!
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
75.45(c) 74.53(c) 77.63(c) 78.46(c) 78.35 Last
2 306 851 3 616 595 1 981 990 2 086 508 2 813 439 Volume
+1.00% -1.22% +4.16% +1.07% -0.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 921 M - -
Net income 2022 389 M - -
Net cash position 2022 486 M - -
P/E ratio 2022 79,6x
Yield 2022 -
Sales 2023 3 515 M - -
Net income 2023 456 M - -
Net cash position 2023 1 518 M - -
P/E ratio 2023 67,1x
Yield 2023 -
Capitalization 30 753 M 30 753 M -
EV / Sales 2022 10,4x
EV / Sales 2023 8,32x
Nbr of Employees 6 300
Free-Float 99,5%
More Financials
Company
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 75.5% of net sales. 
More about the company
Ratings of DexCom, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DEXCOM, INC.
06/30DEXCOM SCHEDULES SECOND QUARTER 2022 : 30 p.m. Eastern Time.
BU
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness ..
BU
06/13DEXCOM, INC. : SPLIT: 4 of 1
FA
06/10DEXCOM INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial St..
AQ
06/08TRANSCRIPT : DexCom, Inc. Presents at William Blair’s 42nd Annual Growth Stock Confer..
CI
06/07Morgan Stanley Adjusts Price Target for DexCom to $363 From $492, Reiterates Equalweigh..
MT
06/06INSIDER SELL : Dexcom
MT
06/02Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Sci..
BU
05/31Wall Street pulls back after last week's rally with inflation in focus
RE
05/31Unilever, DexCom rise; Gold Fields, LivePerson fall
AQ
05/31SECTOR UPDATE : Health Care Stocks Stumble Through Tuesday Trading
MT
05/31S&P edges down after last week's rally with inflation in focus
RE
05/31Equities Slide Midday After Consumer Confidence Declines
MT
05/31MIDDAY REPORT : US Stocks Lower After Consumer Confidence Declines
MT
More news
News in other languages on DEXCOM, INC.
06/29Dexcom e roche collaborano per la distribuzione del sistema di monitoraggio continuo de..
06/06VENTE D'INITIÉS : Dexcom
06/06Valores destacados al cierre del mercado norteamericano
06/01L'île-du-prince-édouard devient un chef de file national en couvrant le système dexcom ..
05/31La Bourse se replie après le rallye de la semaine dernière, l'inflation étant au centre..
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 78,35 $
Average target price 120,89 $
Spread / Average Target 54,3%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-41.55%30 796
ABBOTT LABORATORIES-22.34%191 378
MEDTRONIC PLC-12.53%120 235
BECTON, DICKINSON AND COMPANY0.88%70 676
BAXTER INTERNATIONAL INC.-23.82%32 926
HOYA CORPORATION-31.18%31 359